Therapeutic protein candidates should exhibit favorable properties that render them suitable
to become drugs. Nevertheless, there are no well-established guidelines for the efficient …

Interferon alpha-2b (IFN-α 2b) is an essential cytokine widely used in the treatment of
chronic hepatitis C and hairy cell leukemia, and serum albumin is the most abundant plasma …

Tumor suppressor gene p53 and its aggregate have been found to be involved in many
angiogenesis-related pathways. We explored the possible p53 aggregation formation …

This work unfolds functionalized ABSs composed of FILs ([C2C1Im][C4F9SO3] and [N 1112
(OH)][C4F9SO3]), mere fluoro-containing ILs ([C2C1Im][CF3SO3] and [C4C1Im][CF3SO3]) …

One of the major challenges in formulation development of biopharmaceuticals is improving
long-term storage stability, which is often achieved by addition of excipients to the final …

Computational methods including machine learning and molecular dynamics simulations
have strong potential to characterize, understand, and ultimately predict the properties of …

The design of stable formulations remains a major challenge for protein therapeutics,
particularly the need to minimize aggregation. Experimental formulation screens are …

Protein aggregation (PA) is a critical phenomenon associated with Alzheimer's and
Parkinson's disease. Recent studies have suggested that factors like aggregation-prone …

Interferon-alpha 2b (IFN-α 2b) is a therapeutic protein used for the treatment of cancer, viral
infections, and auto-immune diseases. Its application is hindered by a low bioavailability …

We recently reported the discovery of a novel protein stabilizing dipeptide, glycyl-D-
asparagine, through a structure-based approach. As the starting hypothesis leading to the …